教室業績

• 1) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). Ioka T, Kanai M, Kobayashi S, Sekai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H. Kansai Hepatobiliary Oncology Group (KHBO) J Hepatobiliary Pancreat Sci　2023;30(1):102-110.
• 2) Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer. Shimizu H, Kochi M, Fujii M et al. Discov Oncol. 2023;14(1):111.
• 3) Impact of obstructive ventilatory impairment on intraoperative bleeding during laparoscopic hepatectomy. Nakamura M, Okamura Y, Sugiura T et al. Langenbecks Arch Surg. 2023;408(1):122.
• 4) Loss of viral genome with altered immune microenvironment during tumour progression of Epstein-Barr virus-associated gastric carcinoma.
  Kondo A, Shinozaki-Ushiku A, Rokutan H, Kunita A, Ikemura M, Yamashita H, Seto Y, Nagae G, Tatsuno K, Aburatani H, Koinuma D, Ushiku T. J Pathol. 2023 ;260(2):124-136.
• 5) Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas. Imamura T, Okamura Y, Ohshima K et al. J Hepatobiliary Pancreat Sci. 2023 ;30(3):269-282.
• 6) Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. Nakamura M, Okamura Y, Ohshima K et al. Cancer Med. 2023;12(10):11491-11502.
• 7) Clinical practice guidelines for duodenal cancer 2021. Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y.J Gastroenterol. 2022;57(2):70-81.
• 8) Surgical results of non-ampullary duodenal cancer: a nationwide survey in Japan. Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y; Japan Duodenal Cancer Guideline Committee Dis Esophagus. 2022 ;35(7):doab087. doi: 10.1093/dote/doab087.
• 9) Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
  Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Gastric Cancer. 2022;25(1):188-196.
• 10) Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.
  Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, Itoi T, Unno M, Ohtsuka M, Okusaka T, Kadoya M, Kudo M, Kumada T, Kokudo N, Sakamoto M, Sakamoto Y, Sakurai H, Takayama T, Nakashima O, Nagata Y, Hatano E, Harada K, Murakami T, Yamamoto M. Liver Cancer. 2022;11(4):290-314.
• 11) Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.
  Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, Itoi T, Unno M, Ohtsuka M, Okusaka T, Kadoya M, Kudo M, Kumada T, Kokudo N, Sakamoto M, Sakamoto Y, Sakurai H, Takayama T, Nakashima O, Nagata Y, Hatano E, Harada K, Murakami T, Yamamoto M. Liver Cancer. 2022;11(4):290-314.
• 12) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Hiraoka H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y.
• 13) Current status of selecting type of gastrectomy and reconstruction for patients with proximal gastric cancer in Japan.
  Yamashita H, Toyota K, Kunisaki C et al. Asian J Surg. 2022:S1015-9584(22)01627-X. doi: 10.1016/j.asjsur.2022.11.069.
• 14) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Hiraoka H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y.Gastric cancer. 2022 May;25(3):619-628.
• 15) Evaluation of Safety-Related Outcomes of One-Segment and More-Than-One-Segment High-Level Hepatectomy in Hepatocellular Carcinoma Based on the Japanese Board Certification System. Hojo A, Nakayama H, Okamura Y et al. World J Surg. 2022;46(5):1141-1150.
• 16) Validity of the Algorithm for Liver Resection of Hepatocellular Carcinoma in the Caudate Lobe. Yoshida N , Midorikawa Y, Higaki T et al. World J Surg. 2022;46(5):1134-1140.
• 17) Prospective validation to prevent symptomatic portal vein thrombosis after liver resection.Yoshida N, Yamazaki S, Moriguchi M et al. World J Hepatol. 2022 27;14(5):1016-1024.
• 18) Survival Prediction Capabilities of Preoperative Inflammatory and Nutritional Status in Esophageal Squamous Cell Carcinoma Patients. Sugawara K, Yagi K, Yamashita H et al.World J Surg. 2022;46(3):639-647.
• 19) Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. Imamura T, Okamura Y, Ohshima K et al. BMC Cancer. 2022 5;22(1):1046.
• 20) Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. Imamura T, Okamura Y, Ohshima K et al.Cancer Med. 2022;11(8):1769-1786.
• 21) Pathologic patterns of invasive carcinoma associated with intraductal papillary neoplasms of bile duct (IPNB). Nakanuma Y, Sugino T, Kakuda Y et al. Ann Diagn Pathol. 2022;61:152055. doi: 10.1016/j.anndiagpath.2022.152055.
• 22) Histological pancreatic findings correlate with computed tomography attenuation and predict postoperative pancreatic fistula following pancreatoduodenectomy.
  Sano S, Okamura Y, Ohgi K et al. HPB (Oxford). 2022;24(9):1519-1526.
• 23) Impacts of complications after esophageal cancer surgery on health-related quality of life and nutritional status. Sugawara K, Yagi K, Yamashita H et al. Gen Thorac Cardiovasc Surg. 2022;70(12):1048-1057.
• 24) The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Imamura T, Ohgi K, Okamura Y et al. Pancreatology. 2022;22(5):636-643.
• 25) Optimal settings of near-infrared fluorescence imaging with indocyanine green for intraoperative detection of lymph node metastasis in esophageal cancer.Iwata R, Shiomi S, Yamashita H et al.Gen Thorac Cardiovasc Surg. 2022;70(10):924-929.
• 26) Impact of Tumor Location on the Quality of Life of Patients Undergoing Total or Proximal Gastrectomy. Fujisaki M, Nomura T, Yamashita H et al. J Gastric Cancer. 2022 Jul;22(3):235-247.
• 27) Combining nutritional status with TNM stage: a physiological update on gastric cancer staging for improving prognostic accuracy in elderly patients.
  Sugawara K, Yamashita H, Urabe M et al. Int J Clin Oncol. 2022;27(12):1849-1858.
• 28) Signature and Prediction of Perigastric Lymph Node Metastasis in Patients with Gastric Cancer and Total Gastrectomy: Is Total Gastrectomy Always Necessary?
  Zhang CD, Yamashita H, Okumura Y et al. Cancers (Basel). 2022;14(14):3409.
• 29) Lymphatic invasion is a prognostic factor of pathological N0 esophageal squamous cell carcinoma. Toriumi T, Yagi K, Yamashita H et al. Dis Esophagus. 2022;35(7):doab087. doi: 10.1093/dote/doab087.

II. 症例報告

• 1) Laparoscopic-assisted modified Kugel herniorrhaphy for obturator hernia: a case report. Yamagishi S, Aramaki O, Yoshida N et al. J Surg Case Rep. 2022(2):rjac035. doi: 10.1093/jscr/rjac035.